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INTRODUCTION
Classic Hodgkin lymphoma (CHL) is a lymphoid neopla-
sia characterized by the presence of large pathognomonic 
cells, such as Hodgkin and Reed-Sternberg (HRS) cells, in an 
inflammatory background.1   In Japan, CHL represents 
5–10% of all lymphomas, with a bimodal age distribution, 
and peak incidences being between 15 and 34 years of age 
and between 55 and 84 years of age.2   In contrast, peak inci-
dences of CHL in Western countries, such as the United 
States1 or Germany,3 are predominantly in a younger cohort. 
The majority of patients with CHL have a good clinical 
course with chemotherapy, including doxorubicin, bleomy-
cin, vinblastine, and dacarbazine (ABVD) therapy, and/or 
radiation therapy.   Currently, the 5-year survival rate for 
patients has been reported to be over 95% in a limited stage4,5 
and over 80% in an advanced stage.5,6
The origin of HRS cells had been unknown until recently 
because they frequently express markers of different hemato-
poietic lineages.7,8   Recent studies revealed HRS cells to 
have clonally rearranged immunoglobulin genes with a high 
load of somatic mutations.9-11   Most cases of CHL originate 
from germinal center B-cells.12   However, immunohisto-
chemical analysis often cannot detect B-cell markers, such as 
CD20 and CD79a, in HRS cells.9,13-18   In contrast, the expres-
sion of PAX5 is usually conserved.19   Expression of OCT-2 
and BOB.1, essential transcription factors for immunoglobu-
lin genes, can also be detected in some cases.14,15,20   Previous 
studies reported varying results regarding the expression pat-
terns of these B-cell markers,16,18 although their clinical sig-
nificance has yet to be fully elucidated.   We therefore aimed 
to clarify the clinicopathological significance of CD79a by 
comparing CD79a-positive and CD79a-negative CHL.
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Fifty-five patients, who were initially diagnosed with 
CHL, were examined at Hiroshima Red Cross Hospital & 
Atomic-bomb Survivors Hospital via excisional biopsy 
between 2002 and 2016.   Original diagnoses of CHL were 
confirmed to meet the diagnostic criteria of the WHO 
Classification of Tumours of Haematopoietic and Lymphoid 
Tissues, Revised 4th Edition.1   Patients, who had been 
administered immunosuppressants, such as methotrexate, 
before the initial diagnosis of CHL were excluded.   The use 
of patient specimens and medical records was approved by 
the Institutional Review Board of Hiroshima Red Cross 
Hospital & Atomic-bomb Survivors Hospital.
Histology and immunohistochemistry
The tissue samples used consisted of 51 lymph nodal and 
4 anterior mediastinal biopsy specimens.   The spleen was 
also examined for one patient.   Tissue samples were fixed in 
10% formalin and embedded in paraffin.   Four-micron-thick 
sections were stained with HE.   Immunohistochemical stud-
ies were performed using standard manual methods with the 
Dako REAL™ EnVision™ Detection Systems or via the 
automated stainer BOND-III.   The primary antibodies used 
were as follows: anti-CD30 (Ber-H2, 1:100, Agilent 
Technologies, Santa Clara, CA), anti-CD15 (BY87, 1:40, 
Leica Biosystems, Nussloch, Germany), anti-CD20 (L26, 
1:200, Nichirei Biosciences, Tokyo, Japan), anti-CD79a 
(JCB117, 1:400, Agilent Technologies, Santa Clara, CA), 
anti-PAX5 (1EW, 1:100, Leica Biosystems, Nussloch, 
Germany), anti-CD3 (PS1, pre-dilute, Nichirei Biosciences, 
Tokyo, Japan), anti-BOB.1 (sc-955, 1:200, Santa Cruz 
Biotechnology, Dallas, TX), anti-OCT-2 (sc-233, 1:500, 
Santa Cruz Biotechnology, Dallas, TX), and PD-L1 (E1L3N, 
1:200, Cell Signaling Technology, Danvers, MA).   Based on 
previous studies, a sample was considered positive if ≥10% 
of the tumor cells were stained.14   Furthermore, CD20 and 
CD79a expression was classified into 11 groups by every 
10% cut-off value.
Dual immunohistochemistry for CD79a and CD30 was 
performed for two representative patients using the Leica 
ChromoPlex™ 1 Dual Detection for BOND and BOND-III 
stainer.   The clones of primary antibodies, and their dilution, 
source, enzyme, and chromogen for primary and secondary 
stains were as follows: anti-CD79a (JCB117, 1:25, Agilent 
Technologies, Santa Clara, CA), horseradish peroxidase, 
DAB; anti-CD30 (Ber-H2, 1:20, Agilent Technologies, Santa 
Clara, CA), alkaline phosphatase, and Fast Red, respectively.
Detection of latent Epstein-Barr virus (EBV) infection 
was performed by means of in-situ hybridization for EBV-
encoded small RNAs (EBERs) using PNA Probe/Fluorescein 
and anti-fluorescein isothiocyanate rabbit polyclonal 
antibody.
Statistical analysis
Fisher’s exact test, the chi-square test, and Mann-
Whitney U test were used to examine the differences in char-
acteristics between two groups, as appropriate.   Correlation 
between the proportions of CD79a- and CD20-positive cells 
was examined by the Spearman’s rank correlation coefficient. 
The Kaplan-Meier method was used for analyzing patient 
survival data.   The log-rank test was applied to analyze the 
differences in survival; overall survival (OS) and progres-
sion-free survival (PFS) were considered for the evaluation 
of survival.
The results were considered significant if the P-value was 
less than 0.05.   All data were analyzed using R version 3.4.2.
RESULTS
Clinicopathological findings
Clinical characteristics of the 55 patients with CHL at the 
time of biopsy are summarized in Table 1.   The patients 
included 34 males and 21 females, with a median age of 51 
years (range, 15–86 years).   According to the Lugano 
Classification 2014,21 35 patients were in a limited clinical 
stage (CS) (stage I or II) and 20 were in an advanced CS 
(stage III or IV).   Thirty-eight (69.1%) patients underwent 
biopsy from cervical lymph nodes, whereas 7 (12.7%) under-
went biopsy from infra-diaphragmatic regions.   Extranodal 
involvement included bone marrow, subcutis, lung, liver, 
pleural effusion and/or pleura, kidney, and stomach in 8, 4, 3, 
2, 2, 1, and 1 patients, respectively.   Histological subtypes 
consisted of 27 cases with mixed cellularity (MCCHL), 20 
cases with nodular sclerosis (NSCHL), 6 cases with lympho-
cyte-rich (LRCHL), and 2 unspecified cases.   Forty-eight 
patients (87.3%) were administered ABVD therapy, 12 of 
them also received radiotherapy.   Five patients only received 
radiotherapy.   The 5-year OS and PFS rates were 77.8% and 
57.1%, respectively.
CD79a expression
Out of the 55 patients with CHL, 20 were positive for 
CD79a (Fig. 1); 3 patients with 10–20%, 3 with 20–30%, 5 
with 30–40%, 4 with 40–50%, none with 50–60%, 60–70%, 
or 70–80%, 1 with 80–90%, and 4 with 90–100% (Fig. 2). 
Most of the CD79a-positive cells (19 patients) exhibited 
weaker staining than normal B-cells and plasmacytes.   Each 
HRS cell demonstrated homogenous CD79a staining inten-
sity inside the cytoplasm.
Dual immunohistochemistry in a selected case demon-
strated some HRS cells to be both CD30- and CD79a-
pos i t ive ,  whereas  o thers  were  CD30-pos i t ive  bu t 
CD79a-negative.
CD20 expression and its correlation with CD79a
Out of the 55 patients, 25 were positive for CD20; 15 
patients with 10–20%, 4 with 20–30%, 1 with 30–40%, 2 
with 40–50%, 2 with 50–60%, none with 60–70%, 1 with 
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70–80%, and none with 80–90% or 90–100% (Fig. 2). 
Irrespective of the strength of the staining intensity, it was 
generally confined to the plasma membrane.   There was no 
significant correlation between CD79a and CD20 expression 
(rs = 0.125, P = 0.362).
PAX5 expression
PAX5 was immunohistochemically examined in 15 
CD79a-positive and 20 CD20-positive patients.   Ten were 
positive for PAX5 in the CD79a-positive group, in contrast to 
8 in the CD20-positive group (P = 0.141).
Comparison of the characteristics of patients with CHL 
based on CD79a expression
Patient characteristics were compared between CD79a-
positive and -negative CHL patients (Table 1).   CD79a-
positive patients were significantly older in age at onset (P = 
0.011).   There was no significant correlation between CD79a 
expression and laboratory disease characteristics, including 
serum levels of LDH (P = 1) and sIL-2R (P = 0.251), CS (P 
= 0.203), mediastinal involvement (P = 0.399), extranodal 
involvement (P = 0.749), or the histological subtype (P = 0.108). 
However, the OS and PFS of CD79a-positive patients were 
Variables All CHL cases CD79a-positive CHL CD79a-negative CHL P
Number of patients 55 20 35
Age, median (range) 51 (15–86) 69 (15–82) 37 (17–86) 0.011 †
Sex, male 34 (61.8) 14 (70.0) 20 (57.1) 0.399
LDH > normal * 15 (27.8)   5 (26.3) * 10 (28.6) 1
sIL-2R > normal * 45 (81.8) 14 (73.7) * 31 (88.6) 0.251
Clinical stage 0.203 ‡
I 9 (16.4)   6 (30.0) 3 (  8.6)
II 26 (47.3)   7 (35.0) 19 (54.3)
III   9 (16.4)   3 (15.0)   6 (17.1)
IV 11 (20.0)   4 (20.0)   7 (20.0)
Mediastinal involvement 30 (54.5)   9 (45.0) 21 (60.0) 0.399
Extranodal involvement ** 13 (23.6) 4 (20.0) 9 (24.3) 0.749
Bone marrow 8 (14.5)   3 (15.0) 5 (14.3) 1 
Others   9 (16.4) 2 (10.0) 7 (25.0) 0.462
Histological subtype, specified 0.108 ‡
Mixed cellularity 27 (49.1)   6 (30.0) 21 (60.0)
Nodular sclerosis 20 (36.4) 10 (50.0) 10 (28.6)
Lymphocyte-rich   6 (10.9)   3 (15.0)   3 (  8.6)
Histological subtype, unspecified   2 (  3.6)   1 (  5.0)   1 (  2.9)
Initial treatment N/A
Chemotherapy only 38 (69.1) 13 (65.0) 25 (71.4)
ABVD 36 (65.5) 12 (60.0) 24 (68.6)
Other regimens   2 (  3.6)   1 (  5.0)   1 (  2.9)
Radiotherapy only   5 (  9.1)   4 (20.0)   1 (  2.9)
Combined therapy 12 (21.8)   3 (15.0) 9 (25.7)
ABVD + radiotherapy 12 (21.8)   3 (15.0)  9 (25.7)
Overall survival, months 0.005 §
Median Not reached 141.0 Not reached
Range 3–196 4–181 3–196
Five-year survival rate (%) 80.2 64.6 90.5 
Progression-free survival, months 0.007 §
Median Not reached 28.0 Not reached
Range 0–183 2–176 0–183
Five-year survival rate (%) 63.7 44.0 76.6 
Table 1. Patient characteristics, and histological subtypes of CD79a-positive and CD79a-negative CHL
* Laboratory data were not obtained for one patient
** Mediastinal and splenic lesions are regarded as nodal involvement.
CHL: classic Hodgkin lymphoma; LDH: lactate dehydrogenase; sIL-2R: soluble interleukin-2 receptor.
Fisher’s exact test, two-sided
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significantly inferior to those of CD79a-negative patients (P 
= 0.005 for OS and P = 0.007 for PFS) (Fig. 3).   The 5-year 
OS rates for CD79a-positive and negative patients were 
64.6% and 90.5%, respectively; the PFS rates were 44.0% 
and 76.6%, respectively.   Among 7 CD79a-positive patients 
with advanced-stage disease (CS III or IV), 3 exhibited dis-
ease progression and 2 died despite receiving therapy.   In 
contrast, among 13 CD79a-negative patients with advanced-
stage disease, 2 exhibited disease progression and 1 died.
Subsequently, the proportion of CD79a expression in 
HRS cells was assessed between younger (< 50 years of age) 
and older (≥ 50 years) age groups (Fig. 4).   The older age 
group exhibited a significantly higher proportion of CD79a 
than the younger age group (P = 0.001).   Of note, all patients 
with CD79a expression higher than 80% were in the older 
age group.   In addition, the proportion of CD79a expression 
was compared between limited (CS I or II) and advanced 
stage groups (Fig. 4); both groups had a similar CD79a distri-
bution (P = 0.884).
Clinicopathological features of 5 patients with a high pro-
portion of CD79a-positive HRS cells
Clinicopathological findings in 5 patients in whom the 
majority (> 80%) of HRS cells expressed CD79a are described 
in Table 2.   The patients consisted of 4 males and 1 female, 
aged between 52 and 81 years.   At the time of biopsy, patients 
1–4 were in a limited stage, whereas patient 5 was in CS III. 
Patient 5 was in CS II at initial presentation without mediasti-
nal involvement.   The four patients in a limited stage were 
only administered radiotherapy; 3 of them achieved complete 
response (CR), whereas one had progressive disease (PD). 
In contrast, patient 5 was treated using ABVD therapy, result-
ing in CR.   Patient 2 relapsed after 26 months and died of 
the disease after 55 months.   Patient 3 also died of the dis-
ease after 141 months.   All other patients survived during the 
observation period between 52 and 176 months.   The histo-
logical subtypes consisted of 3 MCCHL and 2 NSCHL.   The 
intensities of CD79a were weaker than in normal B-cells in 
all patients, except in the splenic lesion of patient 5. 
Percentages of CD20-positive HRS cells were small (< 20%) 
in all 5 lymph node specimens, in contrast to that in the 
splenic lesion of patient 5 (70–80%).   EBV was not detected 
in HRS cells of any patient.
DISCUSSION
In this study, 36.4% of the CHL patients were positive for 
CD79a.   This proportion was higher than that reported in 
Fig. 1. (a–c) Classic Hodgkin lymphoma with CD79a expression (> 90%). (a) HE-stained Hodgkin and Reed-
Sternberg (HRS) cells distributed among non-neoplastic small lymphocytes and histiocytes. (b) Neoplastic 
cells identified based on CD30 staining. (c) Most HRS cells were positive for CD79a and showed variable 
staining intensity (arrowhead). (d) Dual immunohistochemistry of CD30 (Fast Red) and CD79a (DAB) in 
another case of classic Hodgkin lymphoma with CD79a expression (30–40%) in which CD79a-positive HRS 
cells expressed CD30, as indicated by an arrowhead.
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Fig. 2. Scatterplot of the proportion of CD20-positive (x-axis) and CD79a-positive (y-axis) HRS 
cells. No significant correlation was found between these B-cell specific antigens (rs = 0.125, P = 
0.362).
Fig. 3. Survival curves of CHL patients with or without CD79a expression. (a) Overall survival (OS). (b) Progression-free survival (PFS). 
There were significant differences between the OS (P = 0.005) and PFS (P = 0.007) of the two groups.
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previous studies (5.7 to 36.0%; Table 3).14-18,22-25   Cut-off val-
ues were not associated with the higher proportion of CD79a-
positive patients because they were set in accordance with 
the previous studies at 10%.14,16-18,22,23,25   Medium-sized 
Hodgkin cells were difficult to distinguish morphologically 
from histiocytes using HE or CD79a single-staining.   Double 
immunohistochemistry of CD79a and CD30 confirmed our 
evaluation of CD79a-positivity based on single staining to be 
mostly accurate.   A possible reason for the high proportion 
of CD79a in the present study was the age distribution.   Our 
study revealed that HRS cells in older patients with CHL, 
especially older patients with NSCHL, often expressed 
CD79a.   A previous study reported that patients older than 
50 years of age had a higher proportion of CD79a-positive 
cells (7 out of 17 patients).18   An epidemiological study in 
Japan reported the second peak incidence of NSCHL to be in 
patients older than 55 years, which is not observed in 
Western countries.1-3   Although the data on patient age in the 
studies listed in Table 3 are insufficient, we consider our cur-
rent study to have included proportionately more older 
patients than the previous reports.   Of note, CD79a expres-
sion was also more common in children.24   A previous study 
reported that LRCHL comprised more CD79a-positive cases 
(42.9%).15   Our current study included only 6 cases of 
LRCHL (10.9%).
CD20 and CD79a are the most widely-used B-cell mark-
ers.   Immunohistochemical findings of CD20 in CHL have 
been more frequently described than those of CD79a. 
Proportions of CD20-positive cases reportedly range from 
4.9% to 35.3% (Table 3).14-18,22,24-27   In previous reports, the 
CD20-positive proportions were slightly higher than the 
CD79a-positive proportions.   Our study also revealed more 
patients to be positive for CD20 (25 patients) than for CD79a 
(20 patients), consistent with the previous studies.   In addi-
tion, older patients were reported to have a higher proportion 
of CD20-positivity than younger patients.18,26-29   As our study 
found no significant correlation between CD79a and CD20 
expression, they may be independent B-cell markers in CHL. 
Indeed, CD20- and CD79a-positivity were reported to be 
only weakly correlated.16   Associations between CD79a and 
B-cell-specific transcription factors were also analyzed in 
previous reports, one of which found a significant positive 
association between OCT-2 and CD79a, but not between 
BOB.1 and CD79a.23
There is limited evidence for the correlation between the 
expression of CD79a and clinical and laboratory disease 
characteristics in CHL.   A previous report found CD79a not 
to be associated with the clinical disease characteristics of 
CHL, including prognosis.23   However, in our study, CD79a-
positive CHL had a poorer prognosis than CD79a-negative 
CHL.   Two of five patients with > 80% CD79a-positive CHL 
cells died of the disease even though they were in a limited 
CS at onset.   This suggests that CD79a-positivity in CHL 
reflects the aggressiveness of the disease.   In contrast to 
CD79a, the prognostic impact of CD20 has been well docu-
mented, although controversies remain.26,28,29
CHL cases sometimes require differential diagnosis from 
aggressive B-cell lymphomas, such as diffuse large B-cell 
lymphoma (DLBCL), especially when the tumor consists of 
relatively high numbers of neoplastic cells with B-cell 
marker expression.   As CD20 and CD79a expression has no 
notable correlation, CD79a should not be considered as a rep-
resentative B-cell marker to discriminate CHL from DLBCL. 
When the expression of B-cell markers does not differ, differ-
ential diagnosis between CHL and DLBCL may be difficult. 
In such situations, confirmation of weaker PAX5 staining or 
Fig. 4. Proportions of CD79a-positive HRS cells according to age and disease stage. Each black triangle or white rectangle 
indicates a patient distinguished by age. There was no difference in the proportion of CD79a expression between limited 
and advanced stage groups (P = 0.884). Older patients were more likely to have more CD79a-positive cells (P = 0.001).
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downregulation of BOB.1 and/or OCT-2 can be useful.   The 
unfavorable clinical outcome of patients with CD79a-positive 
CHL may represent the aggressive characteristics in common 
with DLBCL.   Although patients with DLBCL are often 
classified in a higher CS than those with CHL,30-33 the 
patients with CD79a-positive CHL in our study presented in 
both limited and advanced CS.
CHL highly expressing B-cell markers like CD20 and 
CD79a is controversial regarding its distinction from gray 
zone lymphoma (GZL) or primary mediastinal large B-cell 
lymphoma (PMLBCL).25,34-36   However, mediastinal GZL or 
PMLBCL, whose differential diagnosis from CHL has been 
discussed in many studies, usually develops in younger 
adults.   Therefore, the 5 CHL cases with CD79a-positivity 
higher than 80% had fundamentally different age distribu-
tions and initial tumor localization from mediastinal GZL or 
PMLBCL.   Non-mediastinal GZL should also be taken into 
consideration when diagnosing CHL with high expression of 
B-cell markers; however, it is difficult to discuss due to its 
poorly established diagnostic criteria.37
In conclusion, we found CD79a-positivity in CHL to be 
associated with older age.   In addition, CD79a-positive CHL 
patients had a poorer survival rate than CD79a-negative CHL 
patients.   No positive correlation was observed between 
CD79a and CD20 expression.   Our study suggests that 
CD79a-positive CHL involves unique clinicopathological 
features compared with CD79a-negative CHL.   Further stud-
ies are needed to clarify the characteristics of CD79a-positive 
CHL, especially in Japan, where many patients are older at 
onset.
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